News Sentiment

CRIS sentiment intelligence

Curis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.63 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.7% over one week, -45.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend inactive -45.0% over four weeks
Fair value -95.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 48
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
TradingView 13
Market source 10
PR Newswire 8
simplywall.st 4
Investing.com Canada 2
Simply Wall Street 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 20
Guidance 5
Analyst action 3
Balance sheet 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
grafa.com Direct company coverage

Curis Q2 2026: Updated Clinical Data for Emavusertib Trials

Curis (NASDAQ: CRIS) reported updated clinical data for its emavusertib treatment, showing a 100% objective response rate among five evaluable BTK-naïve lymphoma patients, an increase from 71% in May 2025. The company also expects to dose the first five chronic lymphocytic leukem

Tone
Positive 70/100
Event
Guidance
Published
22 Jul 2026 15:10
Source
grafa.com
Market source Direct company coverage

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) shares surged 11% after the biotechnology company released encouraging updated clinical data for its drug emavusertib in Primary CNS Lymphoma, showing an 86% overall response rate in BTK inhibitor-naïve patients. Regulatory discussions with the FDA and EMA ind

Tone
Positive 74/100
Event
Guidance
Published
22 Jul 2026 12:10
Source
Market source
Investing.com Direct company coverage

Curis stock jumps 11% on positive emavusertib trial data

Curis, Inc. shares surged 11% after announcing positive updated clinical data for emavusertib in Primary CNS Lymphoma, achieving an 86% overall response rate in BTK inhibitor-naïve patients. The company also increased its enrollment guidance for its Chronic Lymphocytic Leukemia s

Tone
Positive 70/100
Event
Guidance
Published
22 Jul 2026 12:10
Source
Investing.com
Investing.com Canada Direct company coverage

Curis reports updated trial data for emavusertib in lymphoma By Investing.com

Curis Inc. announced updated clinical data from its TakeAim Lymphoma study for emavusertib, showing a 100% objective response rate in BTK-naive Primary CNS Lymphoma patients and 33% in BTKi-experienced patients. The company also provided an update on its chronic lymphocytic leuke

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 11:10
Source
Investing.com Canada
TradingView Direct company coverage

Equity in earnings of Curis, Inc. – SWB:CUS1

The article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its equity in earnings, with data sourced from ICE Data Services and FactSet. It indicates that the market for this stock is currently closed, with no trades reported.

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 05:40
Source
TradingView
TradingView Direct company coverage

Long term debt to total equity ratio of Curis, Inc. – SWB:CUS1

This article focuses on the long-term debt to total equity ratio of Curis, Inc. (SWB:CUS1) as presented on TradingView. It appears to be a financial data page rather than a traditional article, providing a snapshot of this key financial metric for the biotechnology company. The c

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jul 2026 04:12
Source
TradingView
TradingView Direct company coverage

Price to book forward of Curis, Inc. – SWB:CUS1

This article provides financial information for Curis, Inc. (SWB:CUS1), specifically focusing on its price-to-book forward ratio. It's listed on the Stuttgart Stock Exchange under Health Technology/Biotechnology. The page displays general financial data, with market data provided

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 22:16
Source
TradingView
Simply Wall Street Direct company coverage

Curis (DB:CUS1) - Stock Analysis

This article provides a detailed stock analysis of Curis (DB:CUS1), a biotechnology company specializing in cancer drug development. It covers the company's valuation, future growth prospects, past performance, financial health, and dividend policy, along with recent news and upd

Tone
Negative 19/100
Event
Capital return
Published
14 Jul 2026 03:16
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Curis, Inc. (CUS1) Company Information

This article provides company information for Curis, Inc. (CUS1), detailing its exchange listings, key information such as its ticker, industry, sector, and market capitalization, and sources of financial data. It also lists the number of employees, location, and the analysts who

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 05:10
Source
Simply Wall Street
TradingView Direct company coverage

Net margin % of Curis, Inc. – DUS:CUS1

This article provides the net margin percentage for Curis, Inc. (DUS:CUS1) on the TradingView platform. It shows the value and change over a period, indicating financial performance. The data is part of a larger financial overview for the company available on the platform.

Tone
Neutral 50/100
Event
Earnings
Published
10 Jul 2026 16:40
Source
TradingView
Stock Titan Direct company coverage

Curis (CRIS) director John Hohneker receives 6,800 stock options at $5.29

Curis Inc. director John Hohneker was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options, which relate to 6,800 shares of common stock, will vest entirely on July 7, 2027, and have an expiration date of July 6, 2036. This transactio

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 01:40
Source
Stock Titan
Stock Titan Direct company coverage

Curis (CRIS) CDO Jonathan Zung receives 48,285 stock options at $5.29 strike

Jonathan B. Zung, Chief Development Officer of Curis Inc. (CRIS), was granted 48,285 employee stock options with an exercise price of $5.29 per share. These options are part of his compensation, designed to vest over time with 25% vesting on July 7, 2027, and subsequent quarterly

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

CURIS (CRIS) CFO receives 48,285 stock options at $5.29 exercise price

CURIS (CRIS) CFO Diantha Duvall was granted 48,285 employee stock options with an exercise price of $5.29 per share as part of her compensation. The options will vest over time, with 25% vesting on July 7, 2027, and subsequent quarterly vesting until July 7, 2030, and will expire

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

CURIS INC (CRIS) director granted 6,800 non-qualified stock options at $5.29

CURIS INC director Anne Elizabeth Borgman was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options will vest 100% on July 7, 2027, and have an expiration date of July 6, 2036. This grant represents compensation-related equity rather t

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

Curis (CRIS) director receives grant of 6,800 non-qualified stock options

Curis Inc. director Kenneth I. Kaitin received a grant of 6,800 non-qualified stock options, exercisable at $5.29 per share. These options, which vest fully on July 7, 2027, and expire on July 6, 2036, are a compensation-related equity award rather than an open-market transaction

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Curis, Inc. – HAM:CUS1

This article provides financial information for Curis, Inc. (HAM:CUS1), specifically focusing on its "Price to book forward" metric. The content appears to be a financial data snippet from TradingView, indicating that the market for HAM:CUS1 is currently closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
TradingView
Stock Titan Direct company coverage

Director Marc Rubin receives 6,800 Curis (CRIS) stock options at $5.29

Curis Inc. director Marc Rubin was granted 6,800 non-qualified stock options at an exercise price of $5.29 per share. These options will vest 100% on July 7, 2027, and have an expiration date of July 6, 2036. This transaction is considered a compensation-related award rather than

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

Curis Inc (CRIS) director receives 6,800 stock options at $5.29

Curis Inc. director Martyn D. Greenacre was granted 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options expire on July 6, 2036, and will vest completely on July 7, 2027. This transaction, categorized as an "A" grant, links the director's com

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Curis Inc For: 9 July By Investing.com

This article reports on a Form 4 filing for Curis Inc. (CRIS) dated July 9th. Form 4 filings are used to disclose changes in beneficial ownership of a company's securities by officers, directors, and 10% shareholders. The specific details of the Form 4 are not provided beyond the

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Investing.com Canada
TradingView Direct company coverage

Free cash flow per share of Curis, Inc. – LSX:A42DTL

This article provides financial information for Curis, Inc. (LSX:A42DTL), specifically focusing on its free cash flow per share. It is presented on TradingView, a platform offering market data and financial tools.

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jul 2026 23:12
Source
TradingView
TradingView Direct company coverage

Price to book forward of Curis, Inc. – FWB:CUS1

The article "Price to book forward of Curis, Inc. – FWB:CUS1" appears to be a stub or a placeholder page from TradingView, specifically concerning the financial metrics of Curis, Inc. (CUS1) on the Frankfurt Stock Exchange. It indicates that there is currently no trade data avail

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 18:12
Source
TradingView
TradingView Direct company coverage

Price to book forward of Curis, Inc. – MUN:CUS1

This article provides financial information for Curis, Inc. (MUN:CUS1) on the Munich Stock Exchange, specifically focusing on its price-to-book forward ratio. It indicates that the market is closed with no recent trades. The content is primarily a data placeholder within a larger

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 09:40
Source
TradingView
TradingView Direct company coverage

Basic earnings per share (basic EPS) of Curis, Inc. – MUN:CUS1

This page provides financial data, specifically the basic earnings per share (basic EPS), for Curis, Inc. trading under the symbol CUS1 on the Munich Stock Exchange. The current market status is closed with no recorded trades.

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 19:13
Source
TradingView
TradingView Direct company coverage

Curis, Inc. Revenue Breakdown – MUN:CUS1

Curis, Inc. (MUN:CUS1) generated 8.04 million EUR in revenue last year, primarily from its "Discovery and Development of Innovative Drug" segment. This figure is down from 10.54 million EUR in the previous year. The United States was the company's largest regional contributor, ac

Tone
Negative 33/100
Event
Earnings
Published
07 Jul 2026 19:13
Source
TradingView